Lawsuit claims Novo Nordisk delayed generic Victoza using patent tactics and settlements, preserving monopoly pricing and ...
Lawsuit alleges a 2019 settlement delayed Teva's generic Victoza launch, with plaintiffs seeking unspecified monetary damages ...
Smith Drug asked the court for an unspecified amount of monetary damages on behalf of a proposed class of Victoza purchasers ...
Danish pharmaceutical giant Novo Nordisk was hit with a class action lawsuit in New York federal court on Friday for allegedly misusing its patents to maintain a monopoly on its diabetes drug Victoza.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results